Kidney Transplantation in Sensitized Recipients; A Single Center Experience by Kim, Sun Moon et al.
INTRODUCTION
In Korea, the number of patients with end stage renal disease
(ESRD) waiting for transplantation continues to increase (1).
Numerous attempts have been made to reduce the number
of waiting patients including the donor-exchange program
and transplantation with ABO incompatible and/or crossmatch
positive donors (2-7). The immune reaction against donor-
antigens remains a barrier to the utilization of kidneys from
living-donors. Although the proportion of sensitized patients
against donor antigens has not been accurately determined
to date, 14% of patients on the United Network for Organ
Sharing waiting list have a history of a high panel reactive
antibody (PRA) titer of more than 80% (8). A preliminary
report from our transplant center showed that 15% of the
patients on the transplantation waiting list have been con-
sidered to be sensitized to human leukocyte antigen (HLA)
antigens, and 8% among them have a PRA titer of more than
50% (unpublished data). ESRD patients, with a positive cross-
match donor, have been prevented from proceeding to trans-
plantation because of the potential risk for developing hyper-
active rejection resulting in graft failure (9). 
Several desensitization protocols have been introduced to
overcome alloimunization with living donor kidney trans-
plantation (10-12). Here we present a single-center experi-
ence with a protocol including pre-transplant plasmaphere-
sis, intravenous immunoglobulin and/or B cell depletion. 
MATERIALS AND METHODS
Patients
From August 2006 to January 2008, seven adult sensitized
patients with ESRD received living donor kidney transplan-
tation at Seoul National University Hospital and were enrolled
in this study. Five patients had a positive crossmatch on the
cytotoxicity or flow cytometric assays, and the other two
patients had donor specific antibodies (DSAs), despite a neg-
ative crossmatch. The patients were scheduled for desensiti-
zation pretreatment, followed by living donor kidney trans-
plantation. Both potential recipients and donors were informed
of the procedures for a positive crossmatch living-donor trans-
plantation protocol, which was compared with transplanta-
tions in cases with a negative crossmatch. 
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Kidney Transplantation in Sensitized Recipients; A Single Center
Experience 
A successful transplantation, across a positive crossmatch barrier, is one of the
most persistent long- standing problems in the field of kidney transplant medicine.
The aim of this study was to describe seven consecutive living renal transplanta-
tions in recipients with positive crossmatch for donors or positive for donor specific
antibodies (DSAs). A preconditioning regimen including plasmapheresis and intra-
venous immunoglobulin was delivered three times a week until the crossmatch and/
or DSAs became negative. Mycophenolate mofetil and tacrolimus were started
two days before the plasmapheresis. The protocol was modified to include admin-
istration of anti-CD 20 antibody (rituximab, 375 mg/m
2) from the patient number 3
through the patient number 7. All seven patients achieved negative conversion of
the crossmatch or DSAs, and the kidney transplantations were successfully per-
formed in all cases. Acute cellular rejection occurred in two patients, which were
subclinical and controlled with high dose steroid treatment. Antibody-mediated rejec-
tion occurred in one patient, which was easily reversed with plasmapheresis. All
recipients attained normal graft function during the 7-24 months of follow up. Our
study suggests that sensitized patients can be transplanted successfully with desen-
sitization pretreatment. 
Key Words : Desensitization, Immunologic; Immunoglobulins, Intravenous; Kidney Transplantation; Plasma-
pheresis; Rituximab
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The desensitization protocol used is summarized in Fig. 1.
The recipients started taking mycophenolate mofetil (MMF,
750 mg twice daily, p.o.) and tacrolimus (0.05 mg/kg twice
daily, p.o., target trough level 10-12 ng/mL) two days before
the first plasmapheresis. Methylprednisolone 1,000 mg i.v.
was started at the time of the surgery, and the steroid dose
was tapered to an oral dose of prednisolone. The combined
immunosuppression of the MMF, tacrolimus and prednisolone
were continued through the post-transplantation period. In
addition, basiliximab (4 mg i.v. on day 0 and day 4) was used
for induction therapy in three patients. The plasmapheresis
(one plasma volume exchange with 4% albumin and/or fresh
frozen plasma) was performed three times a week preopera-
tively. Intravenous immunoglobulin (IVIG, 100 mg/kg) was
administered immediately after each plasmapheresis. After
the second and fifth plasmapheresis, crossmatching and DSAs
were evaluated. Patients with a negative crossmatch and no
donor specific reactivity proceeded to transplantation. The first
and second transplant patients received 10 days of OKT3 (mu-
romonab-CD3) (5 mg daily, i.v.) after the transplantation. We
modified our protocol to include rituximab instead of OKT3
for the treatment of the third patient through seventh patient.
Rituximab (375 mg/m2 of body surface area, i.v.) was admin-
istered three days before the first plasmapheresis and one day
before transplantation until the CD20 and CD19-positive
lymphocytes level was undetectable. The level of CD19-pos-
itive lymphocytes was evaluated before the first use of ritux-
imab and two days before transplantation (12). 
Assessment of antibody status
Donor T cells were isolated from whole blood for cytotox-
icity crossmatching using immunomagnetic beads. A T cell
antiglobulin enhanced complement dependent cytotoxicity
crossmatch (AHG-CDC) was performed using a serial dou-
bling dilution of the recipient’s serum. The last reaction result-
ing in a >20% cell death, above the background, was con-
sidered the anti-donor crossmatch titer. The interpretation
of the flow cytometric crossmatch was performed by direct
comparison of the fluorescence intensity of the donor T cells
after the treatment with the patient’s serum to the intensity
of donor cells after treatment with a negative control serum.
A two-fold change of fluorescence intensity and fluorescence
shift was interpreted as positive. The PRA levels were deter-
mined by commercial ELISA kit (QID; GTI, Waukesha WI,
U.S.A.). Optical density values were assessed to estimate the
level of anti-HLA antibodies, using the value recommended
by the manufacturer. 
Detection and treatment of rejection 
All rejection episodes were biopsy-proven. A biopsy was
performed in the setting of presumed graft dysfunction man-
ifested by oliguria and an elevation of the serum creatinine.
Immunofluorescence staining for IgM, IgA, IgG, C1q, C3,
fibrinogen, kappa, lambda, and the complement degradation
product of C4d was performed in addition to light micro-
scopic examination of the biopsy samples. 
Acute cellular rejection was treated with methylprednisolone
pulse therapy (1,000 mg/day for 3 days). Antibody-mediat-
ed rejection was treated with plasmapheresis followed by
intravenous immunoglobulin (100 mg/kg), rituximab (375
mg/m2 of body surface area, i.v.) plus methylprednisolone
pulse therapy. Plasmapheresis/IVIG was delivered daily until
DSAs decreased to undetectable levels. 
RESULTS
Pre-transplantation characteristics of patients
The clinical and serological characteristics of the seven
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Fig. 1. Desensitization protocol.
Anti-CD 20 Ab, anti-CD 20 antibody; PP, plasmapheresis; IVIG, intravenous immunoglobulin; DSA, donor specific antibody; OP, operation.
Mycophenolate mofetil
Tacrolimus
Steroids
PP
IVIG
Anti-
CD20 Ab
CD 19, 20 CD 19, 20 Crossmatch/DSA Crossmatch/DSA
OP -1 -2 -9 -7 -5 -12 -18 -19 -20 -14 -16
PP
IVIG
PP
IVIG
PP
IVIG
PP
IVIG
PP
IVIG
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Abpatients are shown in Table 1. Six of the transplant recipi-
ents were female. Two patients had received prior transplants,
and three patients had the history of blood transfusion. The
donors of three patients were biologically unrelated husbands.
The average number of donor-recipient HLA mismatches
was 2.9, ranging from two to four. Five patients were cross-
match positive with their donors, and three of them had a
positive flow cytometric, but negative cytotoxic crossmatch
(AHG-CDC). The other two patients had anti-HLA class
I/II antibodies with donor specificity even though they did
not have a positive crossmatch by cytotoxicity or flow cyto-
metric analysis. 
Negative conversion of positive crossmatch
All seven patients achieved a negative crossmatch and/or
negative conversion of DSAs at the time of transplantation.
As crossmatching was not performed after each plasmaphere-
sis, the required number of sessions of plasmapheresis/IVIG
to achieve a negative conversion could not be estimated accu-
rately. All patients had an acceptable alloimmunization sta-
tus after five plasmapheresis/IVIG treatments. Some patients
were given several additional sessions of pre-/post-transplan-
tation plasmapheresis after the crossmatch became negative.
Graft survival and renal function
All patients are alive with normal renal function at a mean
follow-up of 13.2±7.8 months. The post-transplantation
status and outcomes are shown in Table 2. In patient 6, the
serum creatinine increased up to 1.9 mg/dL 62 days after
the transplantation, which appeared to be associated with
tacrolimus toxicity; the serum creatinine level decreased to
1.1 mg/dL after reduction of the tacrolimus dose. The mean
serum creatinine level at the last follow-up was 1.1±0.1
mg/dL. 
Acute rejection
Acute cellular rejection occurred in two patients, and anti-
body-mediated rejection occurred in one patient. Patients 1
and 5 had a renal biopsy 21 days and 13 days after transplan-
tation, respectively. At the time of the renal biopsy the serum
creatinine level was 1.3 mg/dL in both patients. Although
the renal biopsy revealed acute cellular rejection with tubu-
litis and interstitial infiltration of inflammatory cells, these
episodes were subclinical without any definite evidence of
allograft dysfunction except for mild elevation of the serum
creatinine. The patients were treated with bolus methylpred-
nisolone (1,000 mg/day for 3 days). Patient 6, who received
a renal transplant from her brother, was enrolled in the desen-
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Letters in bold indicate alloantigens. Asterisk indicates pre-protocol donor specific antibodies identified. Donor specific antibody was not evaluated in
patient 1-3.
Prior TPL, Number of prior solid organ transplantation the patients had received; HLA, human leukocyte antigen.
Patient
ID
Sex Age
Prior
TPL
Donor
relation
Recipient HLA
AB D R
Donor HLA
AB D R
HLA crossmatch
T-AHG T-Flow
1 F 47 0 Child 11, - 61, 67 12, 16 11, 33 44, 61 7, 12 - +
2 F 24 0 Sibling 26, - 62, - 14, 15 2, 26 62, 75 8, 15 - +
3 F 41 0 Unrelated 2, 11 61, 62 1, 4 3, 11 7, 62 15, -- +
4 F 51 1 Unrelated 2, 24 7, 67 1, 16 2, 24 46, 60* 9, 12 1:1 +
5 F 40 0 Unrelated 2, 11 54, 75 4, 8 2, 24 13*, 75 7*, 9* 1:2 +
6 F 46 0 Sibling 2, 11 51, 61 4, 14 11, 24* 51, 52 4, 15* --
7 M 29 1 Sibling 32, - 44, 58 3, 14 32, 33 44, 58 3, 4* --
Table 1. Baseline clinical and serological characteristics of the patients
PRA, panel reactive antibody; DSA, donor specific antibody; ACR, acute cellular rejection; AMR, antibody-mediated rejection.
Patient
ID
Pre-
protocol
PRA I/II (%)
Post-
protocol
PRA I/II (%)
Pre-
protocol
DSA
Post-
protocol
DSA
Rejection
episodes
F/U 
crossmatch
F/U Cr
(mg/dL)
F/U
duration
(day)
1 30/0 65/-- - ACR 716 1.0 Negative
2 - 0/-- -- 709 1.0 T-flow  (+)
3 - 0/0 -- - 443 1.0 T-flow  (+)
4 58/0 40/0 B60 Negative - 303 1.3 Negative
5 68/80 0/0 DR7, DR9 Negative ACR 205  0.8 -
6 73/47 18/0 A24, DR15 Negative AMR 198  1.4 -
7 58/90 23/50 DR4 Negative - 198 1.3 -
Table 2. Post-transplantation status and outcomesitization protocol because of the pre-protocol presence of
DSAs (A24, DR15). The DSAs were eliminated after two
plasmapheresis/IVIG treatments, and the renal transplanta-
tion was performed after a total of five treatments. Since the
serum creatinine was persistently elevated on three consecu-
tive measurements (peak level of 1.7 mg/dL), a renal biopsy
was performed on post-operative day 14. The renal biopsy
showed antibody-mediated rejection with peritubular capil-
lary C4d staining. The donor specific antibody (DR15) was
detected again at the time of the biopsy. The patient was
treated with bolus methylprednisolone (1,000 mg/day for 3
days) followed by a tapering dose of prednisolone to the pre-
vious dose, and plasmapheresis followed by IVIG (100 mg/
kg) for five days. The serum creatinine was 1.1 mg/dL at hos-
pital discharge. 
Complications
No adverse events associated with infusion of OKT3, rit-
uximab or IVIG were observed. Bleeding occurred in four
patients; three patients received packed-RBC transfusions,
and one patient underwent surgical exploration for bleeding
control. A wound infection occurred in one patient, but it
was controlled with intravenous antibiotics. 
DISCUSSION
Although kidney transplantation in sensitized patients
might be a barrier for successful transplantation, the recent
advances in desensitization enabled the clinicians to expect
good outcomes in graft survival as well as in patient survival
(10-13). Here, we described successful kidney transplanta-
tion in seven recipients who were previously sensitized.
The characterization of anti-donor antibodies is a major
issue in transplantation of sensitized patients (14-16). Anti-
donor antibodies can be detected by several techniques that
vary with respect to their sensitivity and specificity. Many
previous studies enrolled patients with positive cytotoxicity
determined by AHG-CDC. However, recent report has iden-
tified patients with a positive pre-transplant T-flow despite
a negative T-cytotoxicity who have developed acute rejec-
tion associated with impaired long-term graft survival (17).
The role of the DSAs in patients with a negative crossmatch
is controversial (18, 19). One patient in our case series, who
enrolled in the desensitization protocol, due to the pre-trans-
plant presence of DSAs (A24, DR15) despite a negative T-
cytotoxicity and a negative T-flow, developed antibody-medi-
ated rejection 14 days after transplantation. The DSAs were
eliminated after two plasmapheresis/IVIG treatments; how-
ever, they were detected again at the time of rejection. The
culprit antibody was anti-DR15. Large long-term studies
are needed to evaluate the clinical influence of donor specif-
ic antibodies on long-term graft survival.
The proposed protocols that we used were different from
prior procedures in several aspects including the recruitment
of eligible patients for desensitization, use of rituximab or
anti-thymocyte globulin (ATG)/OKT3 and the protocol for
obtaining renal biopsies. IVIG plays an important role in
desensitization protocol (10-13). There are two IVIG proto-
cols: high-dose IVIG and plaspmapheresis/low-dose IVIG
(PP/IVIG). Each protocol has advantages and disadvantages.
High-dose protocol is less expensive, easy to administer, and
does not need live donor. But, some patients might not res-
pond to high-dose IVIG, and antibody removal might be
less rapid. Low-dose IVIG could remove DSAs more rapidly
and effectively, although it needs live donor, more costs and
resources. We have selected the PP/IVIG protocol because
we believe it provides more reliable elimination of DSAs in
the setting of living donor kidney transplantation. Although
PP/IVIG can cause complications such as infections and
immune complex disease, short course therapy is considered
safe. Our results demonstrated that plasmapheresis/IVIG
was effective for decreasing the PRA as well as donor specif-
ic antibodies (Table 2).
Rituximab may be used as part of a preconditioning regi-
men for sensitized patients. It could effectively diminish the
post-plasmapheresis rebound and post-transplantation pro-
duction of anti-donor antibodies by depleting B cells. Though
many desensitization protocols including rituximab have
been introduced, the dosing schedule of rituximab has not
been established. Montgomery et al. (12) reported the week-
ly regimen of rituximab; they administered rituximab 1
month prior to PP/IVIG and dosed (375 mg/m2 body sur-
face area per week, not to exceed four total dose) until the
CD20 and CD19-positive lymphocytes level was unde-
tectable. Gloor et al. (11) introduced single-dose protocol;
they administrerd rituximab (375 mg/m2 body surface area) 4
days before transplantation. However, recent report demon-
strated failure of rituximab therapy in crossmatch positive
renal transplantation (21). Modifying weekly regimen, we
administered rituximab (375 mg/m2 body surface area) at
D-19 and D-1 until the CD20 and CD19-positive cells
were undetectable. 
MMF was also used for inhibition of B cell proliferation.
Although successful protocols without rituximab or splenec-
tomy have been reported (10, 21), rituximab appears to be
beneficial for positive crossmatch transplantation. The use
of rituximab has been associated with false positive cytotox-
ic and flow cytometric results. Although pronase treatment
may overcome this interference (22), it was not used in this
study. Fortunately, none of the five patients that received
rituximab had a false-positive-crossmatch after the use of
rituximab. An improved solid-phase assay might be includ-
ed in future desensitization protocols. OKT3 and antithymo-
cyte globulin have been shown to be effective in crossmatch
positive transplantations (10). After the second patient, we
did not include OKT3 in our protocol. Although two of the
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tion, the actual contribution made by OKT3 to the outcomes
in the present study could not be determined. 
The graft survival in the present study compared favorably
with the results reported by previous studies on positive cross-
match transplantation (10-13). Generally, our protocol con-
sisted of an intensive regimen. Serious complications occurred
in only two patients. One required an exploratory laparoto-
my for bleeding control, and the other received antibiotics
intravenously for the control of a wound infection.
In conclusion, sensitization is not necessarily a contraindi-
cation to the living donor kidney transplantation. Using a
protocol including plasmapheresis/IVIG, tacrolimus, MMF,
and rituximab, seven sensitized patients had successful kid-
ney transplantation. Such protocols for desensitization as well
as donor exchange programs would expand the donor pool,
and may contribute to resolving the organ shortage in trans-
plantation. 
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